Comparative pharmacodynamic evaluation of eptifibatide and Tirofiban HCl in patients undergoing percutaneous coronary intervention (The TAM1 Study)

American Journal of Cardiology

Volumn 93, Issue 10, 2004, Pages 1279-1282

  Saucedo, Jorge F ^b   Garza, Luis ^b   Wolford, David C ^b   Cook, Stephen L ^b   Ramanathan, Kodangudi B ^b   Matin, Zakaria ^b   McGrew, Frank A ^b   Jacoski, Mary V ^b   Jennings, Lisa K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; EPTIFIBATIDE; TIROFIBAN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARKANSAS; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MISSISSIPPI; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TENNESSEE; TYROSINE; UNITED STATES;

EID: 2342545909     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.02.014     Document Type: Article

References (20)

1. Lefkovits J., Plow E.F., Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 332:1995;1553-1559
2. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453
3. Topol E.J., Moliterno D.J., Herrmann H.C., Powers E.R., Grines C.L., Cohen D.J., Cohen E.A., Bertrand M., Neumann F.J., Stone G.W., et al. TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 344:2001;1888-1894
4. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) a randomised, placebo-controlled trial. Lancet. 356:2000;2037-2044
5. Gilchrist I.C., O'Shea J.C., Kosoglou T., Jennings L.K., Lorenz T.J., Kitt M.M., Kleiman N.S., Talley D., Aguirre F., Davidson C., et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 104:2001;406-411
6. Born G.V.R., Cross M.J. The aggregation of blood platelets. J Physiol. 168:1963;178-195
7. Herrmann H.C., Swierkosz T.A., Kapoor S., Tardiff D.C., DiBattiste P.M., Hirshfeld J.W., Klugherz B.D., Kolansky D.M., Magness K., Valettas N., Wilensky R.L. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 89:2002;1293-1297
8. Batchelor W.B., Tolleson T.R., Huang Y., Larsen R.L., Mantell R.M., Dillard P., Davidian M., Zhang D., Cantor W.J., Sketch M.H. Jr, et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes the COMPARE trial. Comparison of Measurements of Platelet Aggregation With Aggrastat, ReoPro, and Eptifibatide. Circulation. 106:2002;1470-1476
9. Kereiakes D.J., Kleiman N.S., Ambrose J., Cohen M., Rodriguez S., Palabrica T., Herrmann H.C., Sutton J.M., Weaver W.D., McKee D.B., et al. Randomized, double-blind, placebo-controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542
10. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II. Lancet. 349:1997;1422-1428
11. Harrington R.A., Kleiman N.S., Kottke-Marchant K., Lincoff A.M., Tcheng J.E., Sigmon K.N., Joseph D., Rios G., Trainor K., Rose D., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 76:1995;1222-1227
12. Jennings L.K., Phillips D.R. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex. J Biol Chem. 257:1982;10458-10466
13. Fitzgerald L.A., Phillips D.R. Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem. 260:1985;11366-11374
14. Phillips D.R., Charo I.F., Parise L.V., Fitzgerald L.A. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 71:1988;831-843
15. Phillips D.R., Teng W., Arfsten A., Nannizzi-Alaimo L., White M.M., Longhurst C., Shattil S.J., Randolph A., Jakubowski J.A., Jennings L.K., Scarborough R.M. Effect of Ca2+ on GP IIb-IIIa interactions with Integrilin enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 96:1997;1488-1494
16. Tcheng J.E., Talley J.D., O'Shea J.C., Gilchrist I.C., Kleiman N.S., Grines C.L., Davidson C.J., Lincoff A.M., Califf R.M., Jennings L.K., et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol. 88:2001;1097-1102
17. Choo J, Gretter DD, Gold HK. Platelet aggregation inhibition with single and double bolus regimens of eptifibatide (Integrilin) (abstr). Am J Cardiol 2000;86(suppl):71I
18. Kereiakes D.J., Lorenz T., Young J.J., Kukielka G., Mueller N.M., Nanniazzi-Alaimo L., Phillips D.R. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis. 12:2001;123-127
19. Jennings L.K., Jacoski M.V., White M.M. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol. 15:2002;45-60
20. Kleiman N.S., Raizner A.E., Jordan R., Wang A.L., Norton D., Mace K.F., Joshi A., Coller B.S., Weisman H.F. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 26:1995;1665-1671